EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
Funding
MyMD Pharmaceuticals raises USD 14 million in Series G and F-1 funding for MYMD-1 in sarcopenia clinical studies
Longevity Tech
May 21, 2024
This week:
Product updates
Stability AI launches Stable Diffusion 3 Medium, a text-to-image model
Foundation Models
Yesterday
Product updates
Microsoft discontinues GPT Builder in Copilot
Generative AI Applications
Yesterday
Funding
BlinqIO raises USD 5 million in funding to expand operations
Generative AI Applications
Yesterday
Product updates
Databricks launches innovations to Mosaic AI for production-quality applications
Generative AI Infrastructure
Yesterday
M&A
Rebellions and Sapeon Korea merge to challenge global AI chip leader
Generative AI Infrastructure
Yesterday
M&A
Pluxee to acquire Cobee; expands employee benefits offering
Remote Work Infrastructure
Yesterday
Product updates
Space and Time launches 'Proof of SQL' solution on GitHub
Enterprise Blockchain Solutions
Yesterday
Partnerships
Lido partners with Mellow Finance to launch liquid restaking vaults
Decentralized Finance (DeFi)
Yesterday
Funding
Rivia raises EUR 3 million in seed funding
Clinical Trial Technology
Yesterday
Product updates
Partnerships
Databricks and Shutterstock collaborate to launch enterprise-optimized ImageAI model
Generative AI Infrastructure
Yesterday
Longevity Tech

Longevity Tech

May 21, 2024

MyMD Pharmaceuticals raises USD 14 million in Series G and F-1 funding for MYMD-1 in sarcopenia clinical studies

Funding

  • MyMD Pharmaceuticals has secured USD 14 million in Series G and Series F-1 private placement rounds. The Series G round was led by strategic investor PharmaCyte, while the F-1 round saw participation from existing shareholders.

  • The company expects to use the funds for the clinical studies of MYMD-1 in sarcopenia (an age-related decline in physical function) for the next two years. MYMD-1 is an orally available, next-generation TNF-alpha inhibitor focused on TNF-alpha-based disease treatment.

  • MyMD is developing novel therapies for serious autoimmune and inflammatory diseases. The company claims that its lead candidate, MYMD-1, has the potential to be the first drug approved by the FDA for sarcopenia. The product is currently in Phase II studies for sarcopenia and frailty—conditions associated with aging—and early-stage trials for rheumatoid arthritis, with the potential for expansion into other applications.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.